Heidi M Soeters1, Shobna Sawry, Harry Moultrie, Annelies Van Rie. 1. *Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC; and †Wits Reproductive Health and HIV Institute, Faculty of Health Sciences, University of The Witwatersrand, Johannesburg, South Africa.
Abstract
BACKGROUND: Many HIV-infected children are diagnosed with tuberculosis (TB), but the effect of TB treatment on virologic and immunologic response to combination antiretroviral therapy (cART) is not well documented. METHODS: Secondary analysis of a prospective cohort of cART-naive HIV-infected South African children aged 0-8 years initiating cART to assess the effect of TB treatment at the time of cART initiation on virologic suppression (HIV RNA < 50 copies/mL), virologic rebound (HIV RNA > 1000 copies/mL after suppression), and CD4 cell percent (CD4%) increase during the first 24 months of cART. RESULTS: Of 199 children (median age 2.1 years), 92 (46%) were receiving TB treatment at cART initiation. Children receiving and not receiving TB treatment at cART initiation had similar median baseline HIV RNA (5.4 vs. 5.6 copies/mL), median time to virologic suppression (6.2 months in each group, adjusted hazard ratio, 1.36, 95% confidence interval: 0.94 to 1.96), and rates of virologic rebound by 24 months (23% vs. 24%, adjusted hazard ratio 1.53, 95% confidence interval: 0.71 to 3.30). Children on TB treatment had significantly lower median CD4% at baseline (15.3% vs. 18.8%, P < 0.01) and during the first 12 months of cART but experienced similar median increases in CD4% at 6 months (9.9% vs. 9.6%), 12 months (14.2% vs. 11.9%), and 24 months of cART (14.5% vs. 14.2%). Exploratory analyses suggest that children receiving lopinavir/ritonavir-based cART and TB treatment may have inferior virologic and immunologic response compared with children receiving efavirenz-based cART. CONCLUSIONS: Receiving TB treatment at the time of cART initiation did not substantially affect virologic or immunologic response to cART in young children.
BACKGROUND: Many HIV-infectedchildren are diagnosed with tuberculosis (TB), but the effect of TB treatment on virologic and immunologic response to combination antiretroviral therapy (cART) is not well documented. METHODS: Secondary analysis of a prospective cohort of cART-naive HIV-infected South African children aged 0-8 years initiating cART to assess the effect of TB treatment at the time of cART initiation on virologic suppression (HIV RNA < 50 copies/mL), virologic rebound (HIV RNA > 1000 copies/mL after suppression), and CD4 cell percent (CD4%) increase during the first 24 months of cART. RESULTS: Of 199 children (median age 2.1 years), 92 (46%) were receiving TB treatment at cART initiation. Children receiving and not receiving TB treatment at cART initiation had similar median baseline HIV RNA (5.4 vs. 5.6 copies/mL), median time to virologic suppression (6.2 months in each group, adjusted hazard ratio, 1.36, 95% confidence interval: 0.94 to 1.96), and rates of virologic rebound by 24 months (23% vs. 24%, adjusted hazard ratio 1.53, 95% confidence interval: 0.71 to 3.30). Children on TB treatment had significantly lower median CD4% at baseline (15.3% vs. 18.8%, P < 0.01) and during the first 12 months of cART but experienced similar median increases in CD4% at 6 months (9.9% vs. 9.6%), 12 months (14.2% vs. 11.9%), and 24 months of cART (14.5% vs. 14.2%). Exploratory analyses suggest that children receiving lopinavir/ritonavir-based cART and TB treatment may have inferior virologic and immunologic response compared with children receiving efavirenz-based cART. CONCLUSIONS: Receiving TB treatment at the time of cART initiation did not substantially affect virologic or immunologic response to cART in young children.
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: C A Wiseman; H S Schaaf; M F Cotton; R P Gie; T Jennings; A Whitelaw; P Roux; A C Hesseling Journal: Int J Tuberc Lung Dis Date: 2011-06 Impact factor: 2.373
Authors: Lilly M Verhagen; Adilia Warris; Dick van Soolingen; Ronald de Groot; Peter W M Hermans Journal: Pediatr Infect Dis J Date: 2010-10 Impact factor: 2.129
Authors: Helen McIlleron; Yuan Ren; James Nuttall; Lee Fairlie; Helena Rabie; Mark Cotton; Brian Eley; Tammy Meyers; Peter J Smith; Concepta Merry; Gary Maartens Journal: Antivir Ther Date: 2011
Authors: C-N Bong; S C C Chen; Y-J Jong; T-S Tok; C-F Hsu; E J Schouten; S D Makombe; J K-L Yu; A D Harries Journal: Int J Tuberc Lung Dis Date: 2007-05 Impact factor: 2.373
Authors: Marcel Yotebieng; Annelies Van Rie; Harry Moultrie; Stephen R Cole; Adaora Adimora; Frieda Behets; Tammy Meyers Journal: AIDS Date: 2010-06-01 Impact factor: 4.177
Authors: Theresa M Rossouw; Ute D Feucht; George Melikian; Gisela van Dyk; Winifred Thomas; Nicolette M du Plessis; Theunis Avenant Journal: PLoS One Date: 2015-07-21 Impact factor: 3.240